The Bronchiolitis Obliterans Syndrome market report also offers comprehensive insights into the Bronchiolitis Obliterans Syndrome market size, share, Bronchiolitis Obliterans Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Bronchiolitis Obliterans Syndrome market size growth forward.
Some of the key highlights from the Bronchiolitis Obliterans Syndrome Market Insights Report:
In 2022, the Bronchiolitis Obliterans Syndrome market size across the 7MM was around USD 58 million and is projected to grow throughout the study period (2019–2032).
Several pharmaceutical companies, including Zambon Pharma, Incyte Corporation, Genentech, GlaxoSmithKline, and Altavant Sciences, are actively involved in developing treatments for Bronchiolitis Obliterans Syndrome.
Strategise your business goals by understanding market dynamics @ Bronchiolitis Obliterans Syndrome Market Landscape
Bronchiolitis Obliterans Syndrome Overview
DelveInsight’s report on the Bronchiolitis Obliterans Syndrome (BOS) treatment market provides a comprehensive overview of the condition, which is an inflammatory disease affecting the smallest airways of the lungs. BOS leads to scarring and airway obstruction due to damage and inflammation caused by various factors, including exposure to chemicals (such as nitrogen oxides, ammonia, welding fumes, and food flavoring fumes), respiratory infections, rheumatoid arthritis, or graft-versus-host disease after lung or hematopoietic cell transplantation.
Symptoms of BOS vary, with some individuals remaining asymptomatic. Common signs include shortness of breath, dry cough, wheezing, and fatigue, which typically develop over weeks or months and may worsen with physical exertion. In some cases, additional symptoms like skin rashes may appear due to chemical exposure.
The condition is linked to lung damage caused by inhaling irritants such as chlorine, sulfur dioxide, and diacetyl, as well as infections from respiratory syncytial virus, adenovirus, or Mycoplasma pneumonia. As BOS progresses, symptoms intensify, highlighting the need for early detection and effective treatment strategies.
Do you know the treatment paradigms for different countries? Download our Bronchiolitis Obliterans Syndrome Market Sample Report
Bronchiolitis Obliterans Syndrome Epidemiology Insights
In 2022, the estimated number of diagnosed prevalent cases of Bronchiolitis Obliterans Syndrome in the 7MM was around 32,600. This number is anticipated to increase throughout the study period from 2019 to 2032.
Bronchiolitis Obliterans Syndrome Epidemiology Segmentation
DelveInsight’s Bronchiolitis Obliterans Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Bronchiolitis Obliterans Syndrome historical patient pools and forecasted Bronchiolitis Obliterans Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Bronchiolitis Obliterans Syndrome Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Bronchiolitis Obliterans Syndrome Prevalence
Age-Specific Bronchiolitis Obliterans Syndrome Prevalence
Gender-Specific Bronchiolitis Obliterans Syndrome Prevalence
Diagnosed and Treatable Cases of Bronchiolitis Obliterans Syndrome
Visit for more @ Bronchiolitis Obliterans Syndrome Epidemiological Insights
Bronchiolitis Obliterans Syndrome Market Outlook
Treatment for Bronchiolitis Obliterans Syndrome (BOS) following lung transplantation or allo-HSCT primarily involves enhancing immunosuppression, as it is considered a form of chronic rejection. This includes increasing or adding immunosuppressive agents such as tacrolimus, cyclosporine, mycophenolate mofetil, and prednisone. Azithromycin has been shown to improve lung function and reduce the incidence of BOS. Additionally, a combination of inhaled fluticasone, oral montelukast, and Zithromax can help slow lung function decline in BOS post-HSCT.
Managing gastroesophageal reflux is also recommended to mitigate BOS progression. In cases where the condition becomes severe and progressive, lung retransplantation may be necessary. Extracorporeal photopheresis has been successfully used to slow lung function decline. Some clinics have recently explored the off-label use of nintedanib and pirfenidone, demonstrating potential clinical efficacy and safety, though further research is needed to establish these drugs as viable therapeutic options for BOS.
Bronchiolitis Obliterans Syndrome Emerging Drugs
Liposomal Cyclosporine A: Zambon Pharma
MPH966 (alvelestat): Mereo Biopharma
Bronchiolitis Obliterans Syndrome Key Companies
Zambon Pharma
GlaxoSmithKline
Incyte Corporation
Mereo Biopharma
Genentech, and others
For more information, visit Bronchiolitis Obliterans Syndrome Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Bronchiolitis Obliterans Syndrome Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Bronchiolitis Obliterans Syndrome, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Bronchiolitis Obliterans Syndrome epidemiology in the 7MM
Bronchiolitis Obliterans Syndrome marketed and emerging therapies
Bronchiolitis Obliterans Syndrome companies
Bronchiolitis Obliterans Syndrome market drivers and barriers
Table of Contents:
1 Bronchiolitis Obliterans Syndrome Market Key Comprehensive Insights
2 Bronchiolitis Obliterans Syndrome Market Report Introduction
3 Competitive Intelligence Analysis for Bronchiolitis Obliterans Syndrome
4 Bronchiolitis Obliterans Syndrome Market Analysis Overview at a Glance
5 Executive Summary of Bronchiolitis Obliterans Syndrome
6 Bronchiolitis Obliterans Syndrome Epidemiology and Market Methodology
7 Bronchiolitis Obliterans Syndrome Epidemiology and Patient Population
8 Bronchiolitis Obliterans Syndrome Patient Journey
9 Bronchiolitis Obliterans Syndrome Treatment Algorithm, Bronchiolitis Obliterans Syndrome Current Treatment, and Medical Practices
10 Key Endpoints in Bronchiolitis Obliterans Syndrome Clinical Trials
11 Bronchiolitis Obliterans Syndrome Marketed Therapies
12 Bronchiolitis Obliterans Syndrome Emerging Therapies
13 Bronchiolitis Obliterans Syndrome: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Bronchiolitis Obliterans Syndrome
16 Bronchiolitis Obliterans Syndrome Market Key Opinion Leaders Reviews
18 Bronchiolitis Obliterans Syndrome Market Drivers
19 Bronchiolitis Obliterans Syndrome Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Bronchiolitis Obliterans Syndrome Epidemiology 2032
DelveInsight’s “Bronchiolitis Obliterans Syndrome – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Bronchiolitis Obliterans Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Bronchiolitis Obliterans Syndrome Pipeline 2024
“Bronchiolitis Obliterans Syndrome Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Bronchiolitis Obliterans Syndrome market. A detailed picture of the Bronchiolitis Obliterans Syndrome pipeline landscape is provided, which includes the disease overview and Bronchiolitis Obliterans Syndrome treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
